このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Morton Toe and Neuromuscular Performance

2026年5月8日 更新者:Nihat Sarıalioğlu、Giresun University

Morton Toe is Associated With Faster Contractile Properties and Superior Reactive Strength in Female Football Players

This cross-sectional observational study investigated whether female football players with Morton toe morphology differ from those with normal foot morphology in neuromuscular contractile properties and kinetic performance characteristics. Morton toe is a congenital foot variation in which the second toe is longer than the first. A total of 47 female football players were classified into two groups based on bilateral foot morphology: Morton foot group (n = 24) and normal foot group (n = 23). Neuromuscular properties of the dominant vastus lateralis muscle were assessed using tensiomyography, and kinetic performance was evaluated through a 40-cm drop jump test on dual force plates. The primary outcomes were contraction time (Tc) and reactive strength index (RSI). Secondary outcomes included relaxation time, delay time, sustain time, maximal displacement, jump height, peak power normalized to body mass, and landing net peak force normalized to body mass. Multiple linear regression models adjusted for age, body mass index, and mean arch index were used to evaluate whether group differences were independent of potential confounders. This study aimed to determine whether Morton toe morphology is associated with distinct neuromuscular and kinetic performance profiles in female athletes.

調査の概要

詳細な説明

Morton toe is a congenital foot morphology characterized by a longer second metatarsal relative to the first. Although traditionally regarded as a clinical or orthopedic variation associated with metatarsal stress fractures and balance difficulties, limited evidence from sprinter populations suggests that a longer second toe may be associated with superior athletic performance. However, no previous study has examined whether Morton toe morphology is related to neuromuscular contractile properties assessed via tensiomyography or kinetic performance derived from force plate testing in a controlled group comparison design.

Participants were screened from 97 female football players. Exclusion criteria included BMI outside the 18.5-29.9 range, bilateral arch index outside the 14-29% range, inconsistent bilateral foot morphology, lower-extremity injury within the past 12 months, neurological or orthopedic conditions, performance-affecting pharmacological use, and menstruation on the measurement day. Morton toe classification was based on the palpation method described by Davidson et al. (2007) with a minimal detectable change threshold of ±0.30 mm.

All measurements were conducted during the off-season to minimize training load interference. Testing followed a standardized sequence: foot morphology assessment, tensiomyography of the dominant vastus lateralis at rest, a 15-minute warm-up, and a 40-cm drop jump test. The assessor was blinded to group classification, and statistical analysis was performed by an independent researcher on a coded dataset. Primary outcome variables (Tc and RSI) were determined a priori. Secondary outcomes were corrected for multiple comparisons using the Holm-Bonferroni method. Regression analyses were performed to assess the independence of group effects from age, body mass index, and mean bilateral arch index.

研究の種類

観察的

入学 (実際)

47

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Centre
      • Giresun、Centre、トルコ(Türkiye)、28100
        • Giresun University - Sports Science Faculty

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

Female football players actively competing in organized leagues in Turkey, recruited from multiple teams during the 2025-2026 off-season period. A total of 97 players were initially screened; 47 met all eligibility criteria and were classified into Morton foot (n=24) and normal foot (n=23) groups.

説明

Inclusion Criteria:

  • Active female football players with a valid sports license for the current season
  • Regular participation in training and competitive matches
  • Bilateral Morton toe morphology (Δ ≤ -0.30 mm on both feet) or bilateral normal foot morphology (Δ > +0.30 mm on both feet)
  • Body mass index between 18.5 and 29.9 kg/m²
  • Bilateral arch index between 14% and 29%
  • Voluntary participation with written informed consent

Exclusion Criteria:

  • Serious lower-extremity musculoskeletal injury within the past 12 months
  • Neurological or orthopedic disease affecting measurement procedures
  • Current use of pharmacological products affecting performance
  • Acute pain, injury, or illness on the measurement day
  • Menstruation on the measurement day (self-reported)
  • Inconsistent bilateral foot morphology classification between feet
  • Bilateral arch index below 14% (high arch) or above 29% (low arch)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Morton Foot Group
Female football players with bilateral Morton toe morphology, defined as a second metatarsal protrusion distance exceeding the first by more than 0.30 mm bilaterally (Δ ≤ -0.30 mm). n = 24.
Normal Foot Group
Female football players with bilateral normal foot morphology, defined as a first metatarsal protrusion distance exceeding the second by more than 0.30 mm bilaterally (Δ > +0.30 mm). n = 23.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Contraction Time (Tc)
時間枠:Single measurement session
Tensiomyographic contraction time of the dominant vastus lateralis muscle, defined as the time between 10% and 90% of maximal radial displacement (ms).
Single measurement session
Reactive Strength Index (RSI)
時間枠:Single measurement session
Jump height divided by ground contact time during a 40-cm drop jump test (m/s). The trial with the highest RSI value out of three attempts was selected for analysis.
Single measurement session

二次結果の測定

結果測定
メジャーの説明
時間枠
Maximal Displacement (Dm)
時間枠:Single measurement session
Peak radial displacement of the vastus lateralis muscle belly during tensiomyographic measurement (mm).
Single measurement session
Relaxation Time (Tr)
時間枠:Single measurement session
Time from 90% to 50% of maximal displacement during the relaxation phase of tensiomyographic measurement (ms).
Single measurement session
Delay Time (Td)
時間枠:Single measurement session
Time from electrical stimulus onset to 10% of maximal displacement during tensiomyographic measurement (ms).
Single measurement session
Sustain Time (Ts)
時間枠:Single measurement session
Duration the muscle response remains above 50% of maximal displacement during tensiomyographic measurement (ms).
Single measurement session
Jump Height (JH)
時間枠:Single measurement session
Vertical jump height calculated from flight time during a 40-cm drop jump test (cm).
Single measurement session
Peak Power Normalized to Body Mass (PPI)
時間枠:Single measurement session
Peak power output normalized to body mass during a 40-cm drop jump test (W/kg).
Single measurement session
Landing Net Peak Force Normalized to Body Mass (LPF)
時間枠:Single measurement session
Peak vertical ground reaction force at landing normalized to body mass during a 40-cm drop jump test (N/kg).
Single measurement session

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月10日

一次修了 (実際)

2026年3月15日

研究の完了 (実際)

2026年3月15日

試験登録日

最初に提出

2026年5月8日

QC基準を満たした最初の提出物

2026年5月8日

最初の投稿 (実際)

2026年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月14日

QC基準を満たした最後の更新が送信されました

2026年5月8日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • GRU-SBF-NS-06
  • 10/492 (その他の識別子:Giresun University Social Sciences, Natural Sciences and Engineering Research Ethics Committee)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する